We are BioCanCell, a clinical-stage biopharmaceutical company dedicated to discovering and developing new therapies to treat cancer. Our lead candidate, BC-819, is a first-in-class, first-of-its-kind potential therapy in late-stage development for non-muscle-invasive bladder cancer.